Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
GlaxoSmithKline
Novartis
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )
ClinicalTrials.gov Identifier:
NCT01352312
First received: May 10, 2011
Last updated: October 18, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2019
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)